Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. - Wikidata - awgldk - TriplyDB

Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.

Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q33401692

about

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study Human amniotic mesenchymal stromal cells (hAMSCs) as potential vehicles for drug delivery in cancer therapy: an in vitro study.Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology.Republished: Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology.Pazopanib in ovarian cancer.Targeting FGFR in Squamous Cell Carcinoma of the Lung.Targeted therapy in esophageal cancer.Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.Pharmacokinetic interaction between pazopanib and cisplatin regimen.Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.Targeted treatments for metastatic esophageal squamous cell cancer Multicompartimental nanoparticles for co-encapsulation and multimodal drug delivery to tumor cells and neovasculature.Pazopanib and liposomal doxorubicin in the treatment of patients with relapsed/refractory epithelial ovarian cancer: a phase Ib study of the Sarah Cannon Research Institute.Treatment of metastatic melanoma with pazopanib: A report of five patient cases.Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin).Bespoke treatment: drivers beware!A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study.

P2860

Q26747666-ACBF53C7-219D-49B6-804D-793E56A96ADE Q27011840-50D70F28-883E-491F-8579-EBA50640CEE4 Q33430940-A50691F7-FA91-41FA-B0E1-08A98044FF4F Q35074974-D82BD965-236A-4483-90C1-AD67695C7069 Q36004194-1736556D-5493-41C7-91CA-B25B485BFAED Q38241160-E97017D5-73AE-4805-8B14-1C39CAD933F1 Q38481540-25ABEAF6-5FA1-4981-8C51-D6A099B1B8C3 Q38571120-FE9CBE30-D44C-47B0-8E33-D4C4C32B8019 Q38690050-2D284A43-7AEE-46DF-A880-C2F4531D878F Q38741042-1077CA8D-EADE-45FC-AC55-D4B3F74AAEAD Q38936104-B4474F6F-5360-428E-B22D-3F477246B7DE Q38964908-190B255B-397D-4171-99A0-18669A890583 Q40094748-F82B480B-93C1-4A9C-9724-925215745A69 Q41658065-2F21EC67-29F6-4523-90EA-12C2EE3CDF60 Q42154615-5C85FCD7-F5E0-4B97-A5CB-C76D1A1A8E8E Q45374613-BB4CACCD-23C8-4CD3-AF7C-EFAB5ADFEE28 Q50591367-0BA2EE90-DEA9-41EE-9B0C-5BB83DE2E18E Q53064579-FDF407C8-939E-4DD6-8E9F-55BD2012C90E Q53167144-DFB7E4B9-6E7E-41D5-A8F6-4EE290F09C91 Q54327170-43925D1E-C00C-483F-B0AE-C053FCF33525 Q55064836-B0610EB2-9444-4C31-BF25-8CE55A69EBE8

P2860

Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q33401692

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Phase I study of pazopanib in ...... ts with advanced solid tumors.

@ast

Phase I study of pazopanib in ...... ts with advanced solid tumors.

@en

type

label

Phase I study of pazopanib in ...... ts with advanced solid tumors.

@ast

Phase I study of pazopanib in ...... ts with advanced solid tumors.

@en

prefLabel

Phase I study of pazopanib in ...... ts with advanced solid tumors.

@ast

Phase I study of pazopanib in ...... ts with advanced solid tumors.

@en

P1433

Q33401692-2EFCF905-2F3C-4F4E-AC56-B970F15C9CF5

P1476

Q33401692-C422C842-F726-48F5-AEA6-716AD63A384C

P2093

Q33401692-294ED32E-3179-42D5-B7B7-AC687A498856

Q33401692-3651A096-764B-4071-A4AF-9BD1E19BCEC2

Q33401692-3AD8B76A-497F-423D-8E37-A9C6FEDB77C0

Q33401692-3BE560D8-4338-4CA4-867D-CBD9B732C37C

Q33401692-41F75729-BD32-4462-BCE9-81C38869B8A5

Q33401692-4CD10103-8DE8-4CBC-B8CF-A2ECE3332ED1

Q33401692-6A16421F-BFFE-4950-87A6-3A2B6A054A9B

Q33401692-AC3D730C-DEE7-4548-8002-07712F3829C1

Q33401692-B82AD13F-FA88-44DA-9298-097B4507A100

Q33401692-C1098F5D-9EB2-4BED-A73F-273B9A200F59

P304

Q33401692-6CF01DFC-93FE-4DB0-BC0E-1BA8080E9C6B

P31

Q33401692-543AC4DC-FC8F-4E3C-832F-6DF7973AD0C5

P356

Q33401692-315A82DC-CE26-4076-BF7A-BF3B05D0753F

P433

Q33401692-3593D7B4-55D6-412D-8D9E-3C7B409E66E4

P478

Q33401692-8E2D2848-1CCF-4D20-B52E-B97FFC45E235

P577

Q33401692-045278CB-04AE-43DC-A0D4-03FCFBC0C6B9

P698

Q33401692-44EF6912-6ECD-43E2-9FF2-43CF7C358983

P921

Q33401692-6B47F0E0-08C3-4704-B2C2-A6B7E38D49DD

Q33401692-DE6EA5E5-B1F1-4809-8759-4B9D50D3E026

P356

1535-7163.MCT-11-0997

P1433

Molecular Cancer Therapeutics

P1476

Phase I study of pazopanib in ...... ts with advanced solid tumors.

@en

P2093

A Benjamin Suttle

http://www.w3.org/2001/XMLSchema#string

Afshin Dowlati

http://www.w3.org/2001/XMLSchema#string

Antoinette R Tan

http://www.w3.org/2001/XMLSchema#string

David R Spigel

http://www.w3.org/2001/XMLSchema#string

Diana Lindquist

http://www.w3.org/2001/XMLSchema#string

Howard A Ball

http://www.w3.org/2001/XMLSchema#string

Howard A Burris

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Infante

http://www.w3.org/2001/XMLSchema#string

Kelly T Levinson

http://www.w3.org/2001/XMLSchema#string

Mohammed M Dar

http://www.w3.org/2001/XMLSchema#string

P304

1820-1828

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-11-0997

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22679111

http://www.w3.org/2001/XMLSchema#string

P921

pazopanib hydrochloride